成纤维细胞生长因子21抗动脉粥样硬化的研究进展  

The research advance of fibroblast growth factor 21 in anti-atherosclerosis

作　　者：谢勇[1] 李东泽[1] 李芳卉 逯光文[3] 曹钰[1] XIE Yong;LI Dongze;LI Fanghui;LU Guangwen;CAO Yu(Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;West China School of Medicine, Sichuan University, Chengdu, 610041, P.R.China;State Key Laboratory of Biological Treatment of West China Hospital, Sichuan University, Chengdu, 610041, P.R.China)

机构地区：[1]四川大学华西医院急诊科,成都610041 [2]四川大学华西临床医学院,成都610041 [3]四川大学华西医院生物治疗国家重点实验室,成都610041

出　　处：《中国胸心血管外科临床杂志》2018年第5期434-439,共6页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：国家自然科学基金(81772037);成都市科技惠民应用示范项目(2016-HM02-00099-SF);四川省卫计委课题资助项目(16PJ305)

摘　　要：成纤维细胞生长因子21(fibroblast growth factor 21,FGF21)是一种多效应的内分泌因子,主要在肝脏和脂肪组织中分泌,具有降脂、抗炎、抗氧化和抗动脉粥样硬化作用。近年来发现,FGF21在心血管疾病中能够诱导保护作用,心血管疾病患者血浆中FGF21水平升高,可作为亚临床动脉粥样硬化的生物标志物,可作为动脉粥样硬化性心血管疾病的治疗靶点。故本文将对FGF21抗动脉粥样硬化作用的最新进展进行综述。Fibroblast growth factor 21 （FGF21） is a multi-effect endocrine factor, mainly secreted in liver and adipose tissue, with the properties of lipid-lowering, anti-inflammatory, anti-oxidant and anti-atherosclerosis. Recent studies found that FGF21 can induce protective effect in cardiovascular disease, and plasma FGF21 levels in patients with disease cardiovascular are elevated. These studies have suggested the use of FGF21 as a biomarker for subclinical atherosclerosis and its potential role in the treatment of established atherosclerotic cardiovascular disease. This article will review the recent advances in the anti-atherosclerosis effect of FGF21.

关 键 词：成纤维细胞生长因子21 动脉粥样硬化 生物标志物 

分 类 号：R543.5[医药卫生—心血管疾病]